Children who interacted with a robot while receiving their shots reported significantly less pain and distress than those in the control group, researchers write in the journal Vaccine.
Nearly 7 months since the FDA approved the blockbuster candidate Eliquis, media reports have shed light on data errors and a case of alleged fraud from clinical trial sites in China. The revelations in reports from Elsevier and Bloomberg could further harm the image of China as a hotspot for clinical development.
Last week Cardio3 BioSciences wrapped up a €23 million IPO, a deal that Forbes contributor Larry Husten argues was based on inconsistent data that he called "highly questionable."
Shares of Cytokinetics ($CYTK) plunged more than 10% this morning after the biotech awkwardly explained a dosing snafu in its sizable midstage study for an experimental treatment for ALS, or Lou Gehrig's disease.
Novartis says that one of its top Phase III drug prospects beat out Enbrel in a head-to-head showdown on psoriasis. Investigators say that the anti-IL17A secukinumab (AIN457) nabbed all the primary and secondary endpoints in the study.
For years, India's poor have been recruited into clinical trials with the promise of life-saving treatment, often without proper consent or education on side effects. Now, as the country works to tighten its regulations, more and more families are suing for retribution.
Parexel has united with the Rutgers New Jersey Medical School in a long-term deal to host clinical trials on campus, giving the school a boost to its clinical research unit.
MannKind is drawing close to raising the curtain on the long-awaited results of late-stage studies of its inhaled insulin Afrezza. And in anticipation of finally achieving success at the FDA, it's adding $160 million in new debt to prepare for a commercial launch.
Bright and early this morning Insmed ($INSM) announced that its inhaled antibiotic Arikace hit its primary endpoint in a Phase III study and was awarded fast-track status at the FDA.
Resverlogix fell hard this afternoon on news that the company fell short in a midstage study of its lead HDL cholesterol-boosting drug. The Calgary-based biotech company said the Phase IIb study of RVX-208 failed to meet the goal of change in percent of atheroma volume in patients with a high risk of developing cardiovascular disease.